Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 7/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415909 | 0.86 | NAE1 (0.39) | ALDH1A1LMNAHPGDEGFR | |
| SCHEMBL5405126 | 0.86 | TAAR1 (0.35) | JAK2JAK3EGFRERBB2KIT | |
| SCHEMBL5407765 | 0.83 | ELOVL1 (0.34) | ELOVL1CYP19A1HTR2C | |
| SCHEMBL5417048 | 0.80 | — | — | |
| SCHEMBL5413218 | 0.79 | PDE5A (0.32) | HTR2CALDH1A1LMNAMAPTPKM | |
| SCHEMBL5416112 | 0.78 | CYP1A2 (0.39) | ELOVL1CYP19A1ALDH1A1JAK2JAK3 | |
| SCHEMBL5415930 | 0.78 | MEN1 (0.41) | ELOVL1CYP19A1ALDH1A1LMNA | |
| SCHEMBL6931879 | 0.77 | TAAR1 (0.38) | ELOVL1JAK2JAK3 | |
| SCHEMBL5414191 | 0.77 | KMT2A (0.35) | — | |
| SCHEMBL5416018 | 0.77 | RXRA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | ELOVL1 4231/4885CYP19A1 656/4885HTR2C 837/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | ELOVL1 4405/4885CYP19A1 719/4885HTR2C 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.